Anika Therapeutics, Inc. ANIK
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 30.59M | 32.61M | 29.61M | 30.62M | 27.82M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 30.59M | 32.61M | 29.61M | 30.62M | 27.82M |
| Cost of Revenue | 11.76M | 11.37M | 10.62M | 11.44M | 12.23M |
| Gross Profit | 18.84M | 21.24M | 19.00M | 19.18M | 15.58M |
| SG&A Expenses | 11.53M | 10.18M | 16.19M | 12.08M | 11.87M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 31.18M | 28.88M | 33.51M | 29.97M | 31.05M |
| Operating Income | -585.00K | 3.73M | -3.90M | 646.00K | -3.23M |
| Income Before Tax | -322.00K | 3.38M | -4.82M | 764.00K | -2.24M |
| Income Tax Expenses | -11.00K | 71.00K | 235.00K | -1.04M | 939.00K |
| Earnings from Continuing Operations | -311.00K | 3.31M | -5.06M | 1.80M | -3.18M |
| Earnings from Discontinued Operations | -- | -- | -- | -1.51M | 846.00K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -311.00K | 3.31M | -5.06M | 292.00K | -2.33M |
| EBIT | -585.00K | 3.73M | -3.90M | 646.00K | -3.23M |
| EBITDA | 854.00K | 5.23M | -2.49M | 1.96M | -1.83M |
| EPS Basic | -0.02 | 0.25 | -0.37 | 0.02 | -0.16 |
| Normalized Basic EPS | -0.01 | 0.19 | -0.15 | 0.03 | -0.10 |
| EPS Diluted | -0.02 | 0.24 | -0.37 | 0.02 | -0.16 |
| Normalized Diluted EPS | -0.01 | 0.19 | -0.15 | 0.03 | -0.10 |
| Average Basic Shares Outstanding | 13.39M | 13.33M | 13.53M | 14.27M | 14.42M |
| Average Diluted Shares Outstanding | 13.39M | 13.72M | 13.53M | 14.67M | 14.42M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |